Advanced search
1 file | 1.01 MB

Biological carrier molecules of radiopharmaceuticals for molecular cancer imaging and targeted cancer therapy

(2014) CURRENT PHARMACEUTICAL DESIGN. 20(32). p.5218-5244
Author
Organization
Abstract
Many tumors express one or more proteins that are either absent or hardly present in normal tissues, and which can be targeted by radiopharmaceuticals for either visualization of tumor cells or for targeted therapy. Radiopharmaceuticals can consist of a radionuclide and a carrier molecule that interacts with the tumor target and as such guides the attached radionuclide to the right spot. Radiopharmaceuticals hold great promise for the future of oncology by providing early, precise diagnosis and better, personalized treatment. Most advanced developments with marketed products are based on whole antibodies or antibody fragments as carrier molecules. However, a substantial number of (pre)clinical studies indicate that radiopharmaceuticals based on other carrier molecules, such as peptides, nonimmunoglobulin scaffolds, or nucleic acids may be valuable alternatives. In this review, we discuss the biological molecules that can deliver radionuclide payloads to tumor cells in terms of their structure, the selection procedure, their (pre)clinical status, and advantages or obstacles to their use in a radiopharmaceutical design. We also consider the plethora of molecular targets existing on cancer cells that can be targeted by radiopharmaceuticals, as well as how to select a radionuclide for a given diagnostic or therapeutic product.
Keywords
non-immunoglobulin scaffolds, nucleic acids, peptides, antibody, targeted therapy, Radiopharmaceuticals, molecular imaging, RECEPTOR-EXPRESSING TUMORS, GLUCAGON-LIKE PEPTIDE-1, HER2-EXPRESSING MALIGNANT-TUMORS, HER2-SPECIFIC AFFIBODY MOLECULE, POSITRON-EMISSION-TOMOGRAPHY, CYSTINE-KNOT MINIPROTEINS, PINHOLE SPECT/MICRO-CT, NON-HODGKINS-LYMPHOMA, IN-VIVO, RADIONUCLIDE THERAPY

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 1.01 MB

Citation

Please use this url to cite or link to this publication:

Chicago
Aerts, An, Nathalie REN Impens, Marlies Gijs, Matthias D’huyvetter, Hans Vanmarcke, Bernard Ponsard, Tony Lahoutte, André Luxen, and Sarah Baatout. 2014. “Biological Carrier Molecules of Radiopharmaceuticals for Molecular Cancer Imaging and Targeted Cancer Therapy.” Current Pharmaceutical Design 20 (32): 5218–5244.
APA
Aerts, An, Impens, N. R., Gijs, M., D’huyvetter, M., Vanmarcke, H., Ponsard, B., Lahoutte, T., et al. (2014). Biological carrier molecules of radiopharmaceuticals for molecular cancer imaging and targeted cancer therapy. CURRENT PHARMACEUTICAL DESIGN, 20(32), 5218–5244.
Vancouver
1.
Aerts A, Impens NR, Gijs M, D’huyvetter M, Vanmarcke H, Ponsard B, et al. Biological carrier molecules of radiopharmaceuticals for molecular cancer imaging and targeted cancer therapy. CURRENT PHARMACEUTICAL DESIGN. 2014;20(32):5218–44.
MLA
Aerts, An, Nathalie REN Impens, Marlies Gijs, et al. “Biological Carrier Molecules of Radiopharmaceuticals for Molecular Cancer Imaging and Targeted Cancer Therapy.” CURRENT PHARMACEUTICAL DESIGN 20.32 (2014): 5218–5244. Print.
@article{6854828,
  abstract     = {Many tumors express one or more proteins that are either absent or hardly present in normal tissues, and which can be targeted by radiopharmaceuticals for either visualization of tumor cells or for targeted therapy. Radiopharmaceuticals can consist of a radionuclide and a carrier molecule that interacts with the tumor target and as such guides the attached radionuclide to the right spot. Radiopharmaceuticals hold great promise for the future of oncology by providing early, precise diagnosis and better, personalized treatment. Most advanced developments with marketed products are based on whole antibodies or antibody fragments as carrier molecules. However, a substantial number of (pre)clinical studies indicate that radiopharmaceuticals based on other carrier molecules, such as peptides, nonimmunoglobulin scaffolds, or nucleic acids may be valuable alternatives. In this review, we discuss the biological molecules that can deliver radionuclide payloads to tumor cells in terms of their structure, the selection procedure, their (pre)clinical status, and advantages or obstacles to their use in a radiopharmaceutical design. We also consider the plethora of molecular targets existing on cancer cells that can be targeted by radiopharmaceuticals, as well as how to select a radionuclide for a given diagnostic or therapeutic product.},
  author       = {Aerts, An and Impens, Nathalie REN and Gijs, Marlies and D'huyvetter, Matthias and Vanmarcke, Hans and Ponsard, Bernard and Lahoutte, Tony and Luxen, Andr{\'e} and Baatout, Sarah},
  issn         = {1381-6128},
  journal      = {CURRENT PHARMACEUTICAL DESIGN},
  keyword      = {non-immunoglobulin scaffolds,nucleic acids,peptides,antibody,targeted therapy,Radiopharmaceuticals,molecular imaging,RECEPTOR-EXPRESSING TUMORS,GLUCAGON-LIKE PEPTIDE-1,HER2-EXPRESSING MALIGNANT-TUMORS,HER2-SPECIFIC AFFIBODY MOLECULE,POSITRON-EMISSION-TOMOGRAPHY,CYSTINE-KNOT MINIPROTEINS,PINHOLE SPECT/MICRO-CT,NON-HODGKINS-LYMPHOMA,IN-VIVO,RADIONUCLIDE THERAPY},
  language     = {eng},
  number       = {32},
  pages        = {5218--5244},
  title        = {Biological carrier molecules of radiopharmaceuticals for molecular cancer imaging and targeted cancer therapy},
  volume       = {20},
  year         = {2014},
}

Web of Science
Times cited: